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Objectives: Thromboembolic events after aortic valve replacement with a biopros-
thesis were the most frequently occurring complications in elderly patients. Whether
this was valve related or dependent on other factors needed further exploration.
Methods: Five hundred patients with a median age of 73 years were followed
retrospectively after aortic valve replacement with a pericardial prosthesis for
occurrence of thromboembolism. Of these, 348 also underwent coronary artery
bypass grafting. Twenty-five factors were investigated for their potential effect by
using univariate and multivariate analysis.
Results: Univariate analysis revealed 6 significant factors: preoperative endocarditis
(P .0001), preoperative cerebrovascular accident (P .002), use of postoperative
warfarin sodium (Coumadin, DuPont Merck; P  .006), arterial hypertension (P 
.023), size of valve prosthesis of 27 mm or larger (P  .023), and hospital
thromboembolism (P  .040). There was a trend toward increased fatal thrombo-
embolism in patients without medication. With a multivariate analysis, 4 factors
remained significant: preoperative cerebrovascular accident (risk ratio, 4.8; P 
.0016), warfarin sodium (risk ratio, 3.0; P  .0028), preoperative endocarditis (risk
ratio, 5.6; P  .006), and hospital thromboembolism (risk ratio, 6.1; P  .016).
Hypertension had a borderline effect. Age, sex, diabetes, 4 coronary artery factors,
3 other valvular factors, atrial fibrillation, and carotid artery disease had no signif-
icant effect.
Conclusions: Some emboli seemed triggered by the valve prosthesis. A proper
anticoagulant protocol but also a treatment of hypertension is important in the
prevention of thromboembolism after aortic valve replacement with a bioprosthesis.
We did not find a significant role of atrial fibrillation and carotid artery disease.
Thromboembolic events after an aortic valve replacement with abioprosthesis are a considerable part of the postoperative morbidityin elderly patients. Our objectives are identification of the riskfactors for thromboembolism and recommendation of therapeuticmeasures in their prevention. Guidelines for reporting morbidity andmortality after cardiac valvular operations defined neurologic non-
hemorrhagic deficits and peripheral arterial emboli as thromboembolic events until
otherwise proved.1 This definition, however, seemed too large and could include
thromboembolic events caused by other factors, such as hypertension, atrial fibril-
lation, other cardiac factors, and carotid artery disease. Thromboembolic events
after aortic valve replacement with a bioprosthesis have been linked to the vascular
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status in earlier reports.2,3 This is of particular importance in
elderly patients, in whom cardiac and vascular comorbidity
is more common. In these patients carotid artery disease can
be screened preoperatively by using a Doppler ultrasono-
graphic technique. The role of anticoagulant medication in
the occurrence of postoperative thromboembolic events in
patients with chronic atrial fibrillation, preoperative cere-
brovascular accidents (CVAs), and postoperative cardiac
events also required exploration.
Patients and Methods
Five hundred consecutive patients receiving a Carpentier-Edwards
Perimount pericardial valve in the aortic position were investigated
retrospectively from 1986 through 2001. In 152 patients only the
aortic valve was replaced; the other 348 patients had a concomitant
procedure, such as a coronary artery bypass grafting (CABG), a
procedure on the ascending aorta (n 27), or a mitral annuloplasty
(n  13). Patients receiving valves in other positions or mechan-
ical valves were excluded. All patients were operated on through
a median sternotomy with standard cardiopulmonary bypass, he-
modilution, and moderate general body hypothermia. Myocardial
protection was obtained with orthograde and retrograde adminis-
tration of a crystalloid cardioplegia solution and topical cooling
with sludge ice.
Potential risk factors that could influence postoperative throm-
boembolic events were recorded. Previous endocarditis was con-
sidered a separate entity.
Warfarin sodium (Coumadin, DuPont Merck) was started on
the day the thoracic drains were removed and continued for 3
months. It was continued only in the presence of other indications,
mostly atrial fibrillation. Antiplatelet (160 mg aspirin daily) drugs
were started in most other patients.
Follow-up was performed by using a questionnaire sent to
cardiologists. Specific attention was given to neurologic deficits
and peripheral arterial emboli. In all patients with a neurologic
deficit, a computed axial tomography (CAT) scan was performed
to exclude hemorrhage. The thromboembolic events were graded
as transient ischemic attack (TIA; resolving within 30 minutes),
reversible ischemic neurologic deficit (RIND; resolving within 24
hours), CVA (ie, with lasting sequelae), or fatal event.
Statistical analysis was performed in a univariate approach by
using the Kaplan-Meier method to determine which of the poten-
tial factors could be of significant prognostic importance. In the
multivariate approach the Cox proportional hazards model was
used to directly relate patient characteristics to the risk of a
thromboembolic event. A 2 analysis was performed to investigate
the interrelation of categoric variables. Hospital thromboembolism
is defined as the occurrence of the event in the first 30 days after
the operation or in the same hospital period if this exceeded 30
days. Long-term thromboembolism is defined as the occurrence of
this event after 30 days postoperatively or after discharge if the
hospital stay exceeded 30 days.
Results
Preoperative Data and Postoperative
Thromboembolism
There were 500 patients (271 male and 229 female patients)
with a median age of 73 years (interquartile range, 71-77
years). They had a median ejection fraction of 65%, (inter-
quartile range, 51%-77%). The mean follow-up was 4.2
years, with a total of 2022 patient-years. Nineteen patients
died within the first 30 days, and a total of 139, or 6.9% per
patient-year, died during follow-up. During hospital stay, a
thromboembolic event, confirmed by means of CAT scan-
ning, occurred in 12 patients. In 3 patients this event was
fatal. The event was a CVA in 5 patients, a RIND in 1
patient, and a TIA in 3 patients. None of the investigated
factors had a significant effect on hospital thromboembo-
lism. Of the 9 surviving patients, 2 had a long-term throm-
boembolism, and none received warfarin sodium.
During long-term follow-up, a thromboembolic event,
also confirmed by means of CAT scanning, occurred in 36
patients, (ie, 1.8% per patient-year). In 12 patients these
were fatal; in 15 patients these events were CVAs (in one as
a result of a postoperative endocarditis, which was treated
medically). The event was a RIND in 2 patients and a TIA
in 6 patients. One patient had an event in the lower limbs.
Individual Relationship of Patient Characteristics to
Risk of Thromboembolism
Table 1 shows the univariate analysis for the investigated
factors, of which 5 had a significant effect on long-term
TABLE 1. Univariate relationship between significant risk factors and occurrence of thromboembolism: the 5-year
event-free rate for the factor present and absent and the P value as obtained from univariate analysis (Kaplan-Meier
method)
Factor TE/n Fatal CVA RIND TIA
5-y event-free  SE
P valueFactor present Factor absent
pCVA 5/26 2 2 0 0 0.79 0.09 0.92 0.02 .002
WARF 11/74 2 8 0 1 0.81 0.06 0.93 0.02 .006
AHT (140/90) 32/349 12 13 1 6 0.90 0.02 0.97 0.02 .023
27 11/85 2 4 0 5 0.81 0.06 0.94 0.01 .023
hTE 2/9 0 2 0 0 0.60 0.22 0.92 0.02 .040
TE, Number of patients with thromboembolism; n, number of patients with factor present; CVA, cerebrovascular accident; RIND, reversible ischemic
neurologic deficit; TIA, transient ischemic attack; pCVA, preoperative cerebrovascular accident; WARF, postoperative use of warfarin sodium; AHT, arterial
hypertension; 27, prosthesis size of 27 mm or larger; hTE, hospital thromboembolism.
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thromboembolism. Preoperative endocarditis is considered
a separate entity: 3 of the 8 patients had a thromboembolic
event that was fatal, but none of the patients had signs of
sepsis. The 5-year event-free rate for thromboembolism in
patients with previous endocarditis was 0.28  0.23 versus
0.92  0.02 in patients without this condition (P  .0001).
Preoperative CVA was significantly more common in
patients with a positive duplex scan result (11.3% vs 4.5%,
P  .049). The severity of aortic valve stenosis was not
different between patients with a positive duplex scan result
and those with a negative duplex scan result: the median
gradients across the valve were 75 mm Hg (60-100 mm Hg)
versus 74 mm Hg (55-94 mm Hg), respectively. Seven
patients with a positive duplex scan result underwent simul-
taneous carotid endarterectomy. They did not have any
postoperative thromboembolic events.
The main reason for treatment with warfarin sodium was
preoperative atrial fibrillation (41.0% vs 9.6%, P  .001).
Another reason was preoperative myocardial infarction
(26.2% vs 13.2%, P  .007). There was a trend toward
postoperative use of warfarin sodium in patients with de-
creased left ventricular function (19.2% vs 13.4%, P 
.096), preoperative CVA (23.3% vs 14.0%, P  .10), and
prior aortic valve replacement (33.3% vs 14.2%, P  .109).
Patients older than 80 years took significantly less warfarin
sodium (5.0% vs 16.1%, P  .036). In 105 patients with
postoperative chronic atrial fibrillation, 4 of 44 patients
receiving warfarin sodium, 1 of 35 patients receiving ace-
tylsalicylic acid, and 3 of 26 patients receiving no medica-
tion had an event. In 374 patients without atrial fibrillation,
7 of 30 patients receiving warfarin sodium, 12 of 185
patients receiving acetylsalicylic acid, and 10 of 159 pa-
tients receiving no medication had an event. There was a
trend toward an increase in fatal events in patients taking no
medication compared with in those taking acetylsalicylic
acid (8/206 vs 2/220, P  .091).
Table 2 shows the nonsignificant parameters. Age greater
than the median did not result in a significant increase in
thromboembolism. Using age as a continuous variable, we
found no significant difference (P  .14).
Simultaneous Relationship of Patient Characteristics
to the Risk of Thromboembolism
Table 3 shows the results of the multivariate analysis. Hos-
pital thromboembolism carries the highest risk ratio. The
effect of size of the valve prosthesis has become nonsignif-
icant, and hypertension is borderline significant. If included,
preoperative endocarditis is also a significant independent
variable for thromboembolism. The other factors remain
highly significant. Although atrial fibrillation was the main
reason to prescribe warfarin sodium, an interaction term
between those 2 factors did not result in a significant effect
(P  .29).
Discussion
Thromboembolism after aortic valve replacement was the
most important valve-related postoperative complication.
These events, however, could be associated with factors
other than valve type.2-5 Whatever the origin might be,
thromboembolism after aortic valve replacement with a
bioprosthesis was regarded as of more importance than
structural failure.6 The annual rate of thromboembolic
events in studies using several valve types ranged from
0.9% to 2.2%,2-6 which was comparable with those in our
series.
TABLE 2. Univariate relationship between potential but
nonsignificant risk factors and occurrence of thromboem-
bolism: P value obtained from univariate analysis (Kaplan-
Meier method)
Factor n
Patients
with TE
P
value
Valvular
Gradient across aortic
valve 75 mm Hg
246 21 .19
Aortic valve regurgitation of
grade II or more
156 10 .50
Previously performed aortic
valve replacement
15 2 .35
Cardiac
Crossclamping time 75
min
115 9 .28
Previously performed CABG 35 3 .29
Implantation of 4
bypasses
59 6 .29
Coronary artery disease on
angiography
327 26 .43
Preoperative atrial
fibrillation
83 7 .56
Preoperative Q-wave
myocardial infarction
61 5 .67
Postoperative chronic atrial
fibrillation
105 10 .68
Episode of atrial fibrillation
within the hospital
189 12 .81
Mitral annuloplasty 13 1 .98
Vascular
Tailoring of the ascending
aorta
27 2 .87
Carotid artery disease on
duplex scan
53 3 .88
Postoperative use of
antiplatelet drugs
220 12 .10
General
Male sex 271 23 .18
Age over the median (73 y) 250 23 .19
Carcinoma in preoperative
history
53 4 .50
Diabetes mellitus 47 4 .82
TE, Thromboembolism; n, number of patients with factor present; CABG,
coronary artery bypass grafting.
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Preoperative medically treated endocarditis in our patient
population was considered a separate condition. High hos-
pital mortality and annual rate of thromboembolism were
found after valve replacement for endocarditis.7,8 One pos-
sible explanation is damage of the endocardium during
infection, creating procoagulant conditions. Regular ultra-
sonographic control after valve replacement is considered
necessary in these patients.
Other valvular factors, such as a valve size of 27 mm or
larger, had a significant effect on postoperative thromboem-
bolism only in a univariate analysis. Larger valve size was
not identified as a risk factor in a previous series.2 Most
series on valve size concerned the effect of the use of
smaller valves and reported mainly on survival.9,10 Neither
the type and severity of aortic valve disease2 nor rereplace-
ment had significant effects on postoperative thromboem-
bolism.2
None of the investigated coronary factors had a signifi-
cant influence on postoperative thromboembolism. Previous
CABG could not be identified as a risk factor after aortic
valve replacement with a Medtronic Hall valve.2 Neverthe-
less, crossclamping time and total bypass time11,12 and a
recent myocardial infarction13 were previously identified as
significant risk factors for postoperative stroke after CABG.
The role of atrial fibrillation in the occurrence of throm-
boembolism remains a matter for debate. No increase in
thromboembolism was found in patients with a Medtronic
Hall valve and preoperative or postoperative atrial fibrilla-
tion,2 yet the long-term risk for thromboembolism was
considerably higher in patients with atrial fibrillation under-
going CABG13 or aortic valve replacement with a Hancock
porcine bioprosthesis.14 In our and other14,15 patient groups,
atrial fibrillation was the main reason for therapy with
warfarin sodium. The effect of warfarin sodium in a series
of patients after aortic valve replacement with a Carpentier-
Edwards pericardial bioprosthesis was studied earlier: an
annual rate of thromboembolism of 0.8% with salicylic
acid, of 1.5% with no treatment, and of 2.9% with warfarin
sodium was observed in retrospect.16 This was considered
as not significant, but a trend is clearly visible (P .07) and
was comparable with the current results. Treatment with
salicylic acid is to be recommended for patients with a
pericardial valve, and the presence of atrial fibrillation re-
quires more frequent ultrasonographic control for detection
of intra-atrial thrombus formation.
In a previous analysis2 hypertension, smoking, and dia-
betes were identified as risk factors for ischemic cerebro-
vascular events, which were labeled as “arterial” and there-
fore unlikely to be altered by the intensity of
anticoagulation. Moreover, use of peroral anticoagulants is
considered as a serious condition with increased mortality.17
A history of preoperative CVA and the occurrence of
hospital thromboembolism were also identified as signifi-
cant independent factors after aortic valve replacement in
octogenarians.18,19 One could link these risk factors with
carotid artery disease. A negative duplex scan result of the
carotid artery, which is considered a reliable diagnostic
tool,20 does not exclude intracranial vasculopathy. Carotid
lesions were not a significant factor for postoperative throm-
boembolism, although in another series asymptomatic pa-
tients with stenosis of the carotid artery of 80% had signif-
icantly more ischemic events.21 Therefore symptomatic
patients with carotid artery stenosis benefit from endarter-
ectomy of the carotid artery. No study directly showed the
consequences of lesions of the carotid artery for neurologic
thromboembolic events after aortic valve replacement, how-
ever.
Hypertension, another vascular factor, was previously
identified as the most important predictor for postoperative
stroke11,12,22,23 and must be controlled tightly. Age in our
population was not a significant factor, probably because
our population was considerably older compared with those
of other studies.2,24
Current and previous results indicate clearly that the
origins of thromboembolism after aortic valve replacement,
with or without association of a CABG, are multiple. After
valve replacement, regions of relative stasis and of flow
with high velocity in varying degree were demonstrated in
all prostheses.25 A postulated mechanism for thromboem-
bolism is platelet activation induced by shear stress, with
adherence to the valve prosthesis and to the atheromatous
plaques on vessel walls. Subsequent embolization to the
cerebral blood flow could be responsible for thromboem-
bolic events, even with small carotid lesions. It seems that
the definition of thromboembolic events offered in the
guidelines1 remains partially valid. Atrial fibrillation and
use of warfarin sodium, which targets the coagulation sys-
tem,2 do not play a role in this hypothetic sequence of
events, which explains partly our counterintuitive results. A
trend toward reduction of fatal thromboembolic events is
observed with acetylsalicylic acid. Moreover, we could as-
sume that small cerebral emboli go unnoticed. Warfarin
sodium could facilitate hemorrhagic transformation, which
could be held responsible for these neurologic events be-
TABLE 3. Simultaneous relationship between the prognos-
tic factors and the risk of thromboembolism obtained with
the Cox proportional hazards analysis
Factor
Risk
ratio 95% CI
P
value
Cerebrovascular accident 4.8 1.8-12.6 .0016
Warfarin sodium 3.0 1.5-6.3 .0028
Hospital thromboembolism 6.1 1.4-26.5 .016
Arterial hypertension 2.7 0.9-7.8 .063
CI, Confidence interval.
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coming symptomatic. This chain of events will probably
remain hypothetical because it is not feasible to perform
regular computed tomographic scans for every patient with
a pericardial valve to detect all emboli. Nevertheless, im-
plantation of aortic valve prostheses can be considered a
minor contributor to cerebrovascular events.
We therefore recommend that use of acetylsalicylic acid
should be promoted strongly, especially in patients with
larger valve size or previously treated endocarditis. The
long-term use of warfarin sodium after aortic valve replace-
ment with a bioprosthesis could be cautiously considered in
elderly patients with atrial fibrillation and previous throm-
boembolic events. These patients should receive regular
ultrasonographic control. Hypertension should be controlled
tightly. If a tissue valve for a certain patient is indicated, a
Carpentier-Edwards pericardial valve can be recommended.
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